Cycle on Jul 27, 2026

I will begin by listing the open threads and watches for this topic to understand what has been prioritized for tracking and if any scheduled events or tripwires have fired.

I will perform searches to investigate the status of the upcoming FDA advisory committee meetings for Capricor's deramiocel (scheduled for July 29, 2026) and Replimune's RP1, as well as the filing acceptance for Saol's SL1009, and other recent major clinical trial or public health updates.

The FDA briefing documents for Capricor's deramiocel (DMD cardiomyopathy cell therapy) were released on Monday, July 27, 2026, ahead of the July 29, 2026 CTGTAC Advisory Committee meeting. This is a massive development. The FDA reviewers stated that the pivotal Phase 3 HOPE-3 trial did *not* meet its pre-specified primary and secondary endpoints, and accused Capricor of changing the statistical analysis plan (SAP) post-unblinding. The stock crashed over 65%. Let's also look for updates on Replimune's RP1 Advisory Committee meeting, Saol SL1009 NDA filing acceptance, and other active threads. I will search for Replimune RP1 AdCom.

The Replimune RP1 briefing documents are expected around now as well because the CTGTAC meeting is on July 30, 2026. Let's do a search for the Replimune briefing documents. If they are published, they should be on the FDA's website. Let's search for "Cellular, Tissue, and Gene Therapies Advisory Committee July 30, 2026 Meeting Briefing Document".

Wow! This is a goldmine of information. First, the RAPS article mentions that an FDA advisory committee (the Pharmacy Compounding Advisory Committee - PCAC) met on July 23-24, 2026. This committee voted to recommend placing 6 of 7 peptides on the 503A bulk drug substances list for pharmacy compounding: BPC-157, KPV, TB 500, MOTS-c, epitalon, and semax, while rejecting emideltide. Interestingly, they overrode FDA staff objections for peptides like epitalon and semax. This relates to the broader policy environment under HHS Secretary Robert F. Kennedy, Jr., who has advocated for more widespread use of peptides. Second, let's search for "Replimune RP1 FDA briefing document July 30 2026" to see if those briefing documents have been posted yet. Since the meeting is on July 30 (Thursday), the briefing materials are expected to be posted 2 business days before, which would be today (Monday, July 27) or tomorrow (Tuesday, July 28). Let's see if there is any news on that.

It seems the briefing documents for Replimune's RP1 have not officially hit the news cycle with major controversy yet, or they might be released on July 28 (tomorrow) given the meeting is on July 30. Let's do a search on the FDA's site or search for the advisory calendar page of July 30, 2026. Let's do a quick search for the July 30, 2026 meeting on `fda.gov`.

Let's fetch the FDA CTGTAC July 30, 2026 meeting announcement to see if any briefing documents have been linked there. Let's do a fetch.

The page doesn't list the briefing documents yet because it says: "FDA intends to make background material available to the public no later than 2 business days before the meeting." Since the meeting is July 30, that would be July 28 (tomorrow). So they aren't posted yet. Wait, let's search for "Saol" and "SL1009" to see if there is any update on the FDA accepting Saol's resubmitted NDA for SL1009 (DCA) in Pyruvate Dehydrogenase Complex Deficiency, which was expected in late July 2026. Let's do a search.

Let's do a broader search for Saol's SL1009 to see if the FDA has accepted the resubmission for filing. Saol resubmitted on July 7, 2026. Usually, a resubmission is reviewed in 30 days for a Class 1 resubmission or 6 months for a Class 2 resubmission. Let's do a search for `"SL1009" FDA accept` or `"SL1009" FDA filing` or `"SL1009" PDUFA`.

Excellent. Let's see if we can find any other news regarding the FDA's acceptance of Saol's resubmitted NDA. Since it was resubmitted on July 7, 2026, the 30-day filing review period would run until early August 2026. Therefore, a formal announcement of filing acceptance and the setting of a PDUFA date might not occur until early August. So this watch (`019f67f8-1a98-7a61-a210-07071f61b308`) has not fired yet, but we have a very solid update on Saol SL1009 resubmission details (including how they aligned with the FDA through Type A and Type C meetings, and how they built their pack with survival data). Let's update `saol-sl1009-dca-fda-resubmission`. Wait, let's also search for other major science/health topics: - Any recent new disease outbreaks or public-health moves? - Any major drug approvals or clinical trial readouts? - What about the H5N1 avian influenza strain in Australia or New Zealand? Let's check. - What about MoonLake's sonelokimab Phase 3 IZAR-1 trial readout in psoriatic arthritis (PsA)? - What about uniQure's BLA submission for AMT-130 in Huntington's disease? - Let's search on H5N1 in Australia or New Zealand.

The H5N1 bird flu situation in Australia and New Zealand is escalating quickly. - In Australia, Queensland has just confirmed its first case (the fourth state to do so, following Western Australia, South Australia, and New South Wales). The case was a dead giant petrel found by park rangers on Moreton Island. This brings the total number of detections in Australia to 18 (or 27 if the 7 new suspected cases in South Australia reported on Monday, July 27, are confirmed). - In South Australia, 7 new suspected cases were reported on July 27, 2026, in greater crested terns on the Limestone Coast. - Crucially, there are *no* detections in commercial poultry in Australia yet, and the risk to human health remains low. - In New Zealand, the first case of H5N1 was confirmed on July 10 (a sick brown skua found on Petone Beach), followed by a second case confirmed on July 17 (a swamp harrier hawk in the Wairarapa). - Local wildlife sanctuaries and colonies are taking high-level biosecurity measures. For example, Oamaru's little penguin colony and the Wingspan National Bird of Prey Centre (falcon sanctuary) are preparing with shoe baths, visitor restrictions, and other biosecurity protocols. - There are still no H5N1 detections in commercial poultry in New Zealand either. Let's check if the watch triggers: - `New Zealand H5N1 transmission to poultry or wildlife sanctuaries` (`019f776d-f69b-75cf-93b1-ae8e6c95e559`): "Fires when New Zealand confirms H5N1 transmission to commercial poultry operations, wildlife sanctuaries, or local marine mammal colonies." It has not fired yet because there are no poultry cases or confirmed wildlife sanctuary transmissions, though sanctuaries are proactively locking down. - `Australia H5N1 transmission to poultry or local wildlife` (`019f2f50-7f4d-7361-8f05-cdf170c2d727`): "Fires when Australia confirms the transmission of H5N1 to commercial poultry flocks, native land birds, or local marine mammal colonies." Wait, has it spread to local wildlife? The cases in Australia are currently in wild birds (seabirds like petrels and greater crested terns), but what about native land birds or local marine mammals? In June, scientists revealed that 13,000 seal pups died on the subantarctic Heard and McDonald Islands, but those are subantarctic territories, not mainland local marine mammal colonies or commercial poultry. So we should keep monitoring this. Let's do a search on other areas of interest: - Let's check MoonLake's sonelokimab Phase 3 IZAR-1 trial readout in psoriatic arthritis (PsA) which was expected in mid-2026. - Let's check uniQure's AMT-130 BLA submission in Huntington's disease (expected Q3 2026). - Let's check Vera Therapeutics' Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN (expected Q3 2026). - Let's check if there is any other major health or science news. Let's run a search for "MoonLake sonelokimab IZAR-1".

Ah, the MoonLake sonelokimab IZAR-1 trial readout in PsA is expected in Q3 2026 (or "mid-2026"). It doesn't seem to have read out yet, but they recently announced positive Phase 2 data in axial spondyloarthritis. Let's do a search on that axial spondyloarthritis Phase 2 data to see if we should write a note on it or wait for the Phase 3 PsA readout. Let's check "MoonLake sonelokimab axial spondyloarthritis Phase 2".

Ah, my web_search budget is spent. I have plenty of fresh, high-quality, primary evidence to write up notes. Let's carefully analyze what we have: 1. **Capricor's deramiocel FDA Advisory Committee briefing documents**: - Slug: `fda-regulatory-pivot-advisory-committees-capricor-replimune` (Wait, let's look at the prior findings. The prior finding is titled "The Post-Makary FDA Pivot: Back-to-Back AdComs Confirmed for Capricor's Deramiocel and Replimune's RP1" with slug: `fda-regulatory-pivot-advisory-committees-capricor-replimune`). - Let's update `fda-regulatory-pivot-advisory-committees-capricor-replimune` in place using `write_note`. - Wait, let's review the details: The FDA briefing documents were released on Monday, July 27, 2026, ahead of the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meeting on Wednesday, July 29, 2026. - The FDA staff reviewer documents disagreed with Capricor's claims of success in the Phase 3 HOPE-3 trial, stating the trial did *not* meet pre-specified primary or secondary endpoints. They accused Capricor of changing the statistical analysis plan (SAP) post-hoc and after unblinding (generating at least two additional versions, with the FDA's analysis relying on SAP version 1.1, while Capricor asserts version 3.0 was finalized prior to unblinding). They also noted potential unblinding due to distinct safety profiles (42% hypersensitivity reactions in deramiocel vs 15% in placebo). This caused the stock to plummet over 65%. - This is an incredible and highly consequential update on this exact slug. 2. **H5N1 Avian Influenza in Australia and New Zealand**: - Let's check if there is an existing slug. Looking at the threads, we have: - `New Zealand H5N1 transmission to poultry or wildlife sanctuaries` (slug: `new-zealand-h5n1-transmission-to-poultry-or-wildlife-sanctuaries`? No, let's check if there are prior notes. None of the prior findings retrieved are about H5N1, but the threads list H5N1 in NZ and Australia as watches. Let's create a new note or update an existing one if it exists. Wait, let's call `read_notes` to see if there is an existing note on H5N1 in Australia/NZ.) Let's call `read_notes` to check the slugs of existing notes. This is a very smart step to avoid coining a near-synonym. Let's do that!

This is amazing. I can see several slugs here and I can map our findings directly to them! Let's see: 1. `fda-regulatory-pivot-advisory-committees-capricor-replimune` is perfect for Capricor's deramiocel FDA briefing document and upcoming CTGTAC meeting. 2. `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` is perfect for the H5N1 update in Australia and New Zealand. 3. `saol-sl1009-dca-fda-resubmission` is perfect for Saol's SL1009 NDA resubmission update. 4. Wait, what about the FDA Pharmacy Compounding Advisory Committee (PCAC) recommending 6 of 7 peptides (BPC-157, TB-500, KPV, MOTS-c, epitalon, semax) on the 503A bulks list? This is a massive, highly consequential health/policy and regulatory story. Under RFK Jr.'s HHS, this is a major breakthrough. Let's create a new note with a fresh slug for this: `fda-compounding-advisory-committee-peptide-recommendations`. It's a brand-new story. Let's carefully verify if any of our watches have fired or can be updated: - `FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy` (`019f061f-f34a-7079-a276-d216329928b2`): The fire date is July 29, 2026. The meeting hasn't happened yet (today is July 27), so we shouldn't resolve it yet. We'll leave it open for the next cycle to resolve when the meeting actually votes. - `FDA advisory committee meeting and PDUFA date for Replimune's RP1 in advanced melanoma` (`019f0620-0add-7ac7-9db1-1ce428418522` or `019f0620-007b-7dab-87b4-0363a2496ea1`): The meeting is on July 30, 2026, so it hasn't fired yet either. - `FDA filing acceptance and PDUFA date for Saol's SL1009` (`019f67f8-1a98-7a61-a210-07071f61b308`): This is expected in late July 2026 or early August 2026 (since Saol resubmitted on July 7, 2026, the 30-day review period ends in early August). It hasn't fired yet either, but we have a useful update on the resubmission. - `Australia H5N1 transmission to poultry or local wildlife` (`019f2f50-7f4d-7361-8f05-cdf170c2d727`): Let's see if H5N1 has transmitted to native local wildlife. In Australia, the cases are in wild birds (seabirds like petrels and greater crested terns), but there are no poultry cases or marine mammal cases confirmed on mainland Australia yet. Wait! The watch says: "Fires when Australia confirms the transmission of H5N1 to commercial poultry flocks, native land birds, or local marine mammal colonies." So far, there is no transmission to commercial poultry flocks, native land birds (only migratory/non-migratory seabirds like petrels and greater crested terns), or local marine mammal colonies on mainland Australia (the 13,000 seal pups were on subantarctic Heard and McDonald Islands, which are subantarctic territories, not mainland local colonies). So this watch has not fired yet, but it is ongoing, and we have major updates on wild seabirds. - `New Zealand H5N1 transmission to poultry or wildlife sanctuaries` (`019f776d-f69b-75cf-93b1-ae8e6c95e559`): No poultry cases or wildlife sanctuary transmissions have been confirmed yet, though wildlife sanctuaries are doing strict lockdowns. So this watch also hasn't fired yet. So no watches have officially fired, but we have massive updates to existing notes and one brand-new note! Let's write the first note: **Capricor's deramiocel FDA Briefing Documents**. Slug: `fda-regulatory-pivot-advisory-committees-capricor-replimune` Wait, let's look at the prior note title: "The Post-Makary FDA Pivot: Back-to-Back AdComs Confirmed for Capricor's Deramiocel and Replimune's RP1" We will update it to reflect the dramatic turn of events with the release of the briefing documents on July 27, 2026. Let's structure the note body for `fda-regulatory-pivot-advisory-committees-capricor-replimune`: We must name and link the actual source: - BioSpace article: `https://www.biospace.com/drug-development/fda-disputes-capricors-claims-of-phase-3-success-for-dmd-cell-therapy` - Quote: “did not meet its pre-specified primary and secondary efficacy endpoints, showing no statistically significant difference between deramiocel and placebo at 12 months.” - Quote: “The distinctive adverse event profile observed between treatment groups—hypersensitivity reactions seen in 42% of deramiocel-treated patients versus 15% of placebo-treated patients—raises the possibility that treatment assignment could be inferred even under formal blinding conditions,” - Quote from Linda Marbán (CEO): “It’s been very disconcerting to us... We take great issue with how FDA analyzed the data using [SAP version 1.1].” - Interpret: This represents a major setback for Capricor. The FDA reviewers took issue with post-unblinding changes to the Statistical Analysis Plan (SAP) and potential unblinding due to distinct safety profiles. The stock plummeted over 65% on the news. This sets up a highly contentious CTGTAC meeting on July 29, 2026. Let's write this note first. No YAML frontmatter. First heading is `# <Title>`. No bare paths or hand-built URLs for other findings, use `[[slug]]` wikilinks. Let's draft it.

Now let's write the second note about the **H5N1 Avian Influenza spread in Australia and New Zealand**. Wait, what is the existing slug? Let's check `read_notes` output. There are a few H5N1 slugs: - `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` ("H5N1 Avian Influenza Breaches New Zealand: First Native Bird Case and Poultry "Flockdown" Imposed") - `h5n1-avian-influenza-arrival-new-zealand` ("H5N1 Avian Influenza Arrives in New Zealand, Triggering Emergency Wildlife Vaccinations") - `australia-h5n1-avian-influenza-seabirds` ("Australia's H5N1 Bird Flu Cases in Migratory Seabirds Grow to Eight as Surveillance Ramps Up") - `h5n1-bird-flu-arrival-oceania` (Wait, `h5n1-bird-flu-arrival-australia-new-zealand` is "H5N1 Bird Flu Arrives in Oceania: First Local Detections Confirmed in Australia and New Zealand") - `australia-h5n1-wildlife-transmission` ("Australia H5N1 Escalation: First Case Confirmed in Local Native Seabird on Mainland") Wait, which is the most comprehensive slug that we should update? Let's see: `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` was updated on `2026-07-26T22:48:11Z` (which is yesterday!). Let's update `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns` to add the very latest: - Queensland has confirmed its first case (migratory seabird, a dead giant petrel on Moreton Island), making it the fourth Australian state to do so. This brings total confirmed detections in Australia to 18. - South Australia reported 7 new suspected cases on July 27, 2026, in greater crested terns on the Limestone Coast. If confirmed, this would bring the total to 27. - Still no detections in commercial poultry in Australia. - New Zealand has confirmed its second case (swamp harrier hawk in Wairarapa on July 17). - Wildlife sanctuaries are implementing strict biosecurity measures (Oamaru's penguin colony, Wingspan National Bird of Prey Centre) with shoe baths and visitor restrictions. - Still no detections in commercial poultry in New Zealand. Let's prepare the updated note for `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns`. We will cite: - Global Ag Media / Poultry Site article: `https://www.thepoultrysite.com/news/2026/07/australia-confirms-fourth-case-of-h5n1-in-queensland` - Quote: "Queensland became Australia's fourth state to confirm a case of H5N1 bird flu after authorities said on Saturday that a migratory seabird tested positive... There remain no detections in poultry, nor evidence of large-scale deaths in any animals in Queensland" - News.Az / Reuters article: `https://news.az/news/south-australia-reports-seven-new-suspected-h5n1-bird-flu-cases` - Quote: "South Australian authorities on Monday reported seven new suspected cases of the deadly H5N1 bird flu strain... all seven suspected cases were identified in greater crested terns on the Limestone Coast" - Stuff.co.nz article: `https://www.stuff.co.nz/nz-news/361009689/falcon-sanctuary-prepares-for-bird-flu-with-shoe-baths-and-visitor-restrictions` - Quote: "Wingspan National Bird of Prey Centre has introduced strict shoe baths and visitor restrictions... to protect its native birds from the highly contagious virus" Let's write this updated note. No YAML frontmatter. First heading is `# <Title>`. Use `[[slug]]` wikilinks for other findings if necessary. Let's write.

Now let's write the third note about the **FDA Pharmacy Compounding Advisory Committee (PCAC) peptide recommendations**. This is a brand-new, highly consequential, on-topic story. It fits the topic brief perfectly ("disease outbreaks and public-health moves, drug approvals and major trial readouts, breakthroughs in biology/energy/space, and the policy around them"). Let's name it: `fda-compounding-advisory-committee-peptide-recommendations`. Title: `FDA Compounding Committee Overrides Staff Objections to Recommend Six Peptides for Bulk Compounding` We will cite: - RAPS article: `https://www.raps.org/resource/fda-advisory-committee-backs-two-more-peptides-rejects-one-for-compounding-list.html` - Quote: "By the end of a two-day meeting that concluded Friday afternoon, an advisory committee to the US Food and Drug Administration (FDA) voted in favor of adding six of the seven peptides it was tasked to review to the list of bulk drug substances that can be used in pharmacy compounding." - Quote: "The committee voted in favor all four of the substances—BPC-157, KPV, TB 500, and MOTS-c—it considered during a session that ran hours late on Thursday. On Friday, the committee voted in support of two of the three peptides on the docket, epitalon and semax, while it rejected adding emideltide to the list." - Quote: "As it did the previous day, the advisory committee voted to override FDA staff objections and recommended that epitalon be placed on the list with a vote of 7-5, with one member abstaining." - Interpret: This is a major policy shift. The FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding six popular peptides to the 503A Bulks List, overriding FDA staff safety and characterization objections for several of them (particularly epitalon and semax). This comes amidst a broader push under HHS Secretary Robert F. Kennedy, Jr., who has publicly supported wider access to peptides and alternative therapies. Let's write this note. No YAML frontmatter. First heading is `# <Title>`. Let's do it.

Now let's write the fourth note about **Saol Therapeutics' SL1009 NDA resubmission**. Wait, what is the existing slug? Let's check `read_notes` output. The existing slug is `saol-sl1009-dca-fda-resubmission`. Let's see: "Saol Therapeutics Resubmits NDA for SL1009 (DCA) in Pyruvate Dehydrogenase Complex Deficiency Following Post-Makary FDA Alignment" Let's update this note to add the newly surfaced details: - Saol resubmitted on July 7, 2026. - The resubmission follows a Type A meeting in December and a subsequent Type C meeting where the FDA and Saol aligned on the content of the submission package (the FDA advised that a Type C meeting would be quicker to agree on the package content rather than directly resubmitting). - Saol's resubmitted package includes new survival data. - SL1009 (sodium dichloroacetate / DCA) is being developed for pyruvate dehydrogenase complex deficiency (PDCD), an ultra-rare life-threatening mitochondrial disease with no FDA-approved therapies. - The FDA's rejection of SL1009 under former Commissioner Marty Makary last August had drawn severe criticism from patient groups (like the Cure MITO Foundation and United Mitochondrial Disease Foundation) who warned that delays could cause irreversible damage or death. - This resubmission is part of a broader wave of "post-Makary" reversals/resubmissions (including REGENXBIO and Replimune) benefiting from a more flexible post-Makary FDA. Let's prepare the updated note for `saol-sl1009-dca-fda-resubmission`. We will cite: - BioSpace article: `https://www.biospace.com/fda/saol-boards-fdas-resubmission-boat-armed-with-new-survival-data` - Quote: "During the Type A meeting in December, Saol—pronounced “Sail”—asked to “directly” resubmit the application for SL1009, but the FDA advised that it would be quicker to first participate in a Type C meeting so both parties could agree on the content of the submission package, CEO Dave Penake recalled." - Quote: "If the agency does accept Saol’s new filing, SL1009 will be the latest therapy to benefit from the FDA’s newfound flexibility after the spring departures of former Commissioner Marty Makary and Center for Biologics Research and Evaluation (CBER) director Vinay Prasad." - Yahoo Finance / Biotech Hangout article: `https://finance.yahoo.com/healthcare/articles/prime-wins-gene-editing-dispute-090700525.html` - Quote: "Saol on Tuesday said it resubmitted an application for SL1009, a potential treatment for the rare disease pyruvate dehydrogenase complex deficiency that the FDA turned back last August." Let's write this updated note. No YAML frontmatter. First heading is `# <Title>`. Use `[[slug]]` wikilinks for other findings if necessary. Let's do it.

Excellent. We have updated three existing notes and written one new note. Let's double-check the rules: - "Call list_threads to see what the user wants pursued — and what you're already watching for." (Done) - "Gather and CONFIRM evidence using whichever source tools fit this topic." (Done) - "For each distinct theme or story worth persisting, call write_note — ONE note per theme, never a combined write-up." (Done, we wrote/updated four notes: `fda-regulatory-pivot-advisory-committees-capricor-replimune`, `h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns`, `fda-compounding-advisory-committee-peptide-recommendations`, and `saol-sl1009-dca-fda-resubmission`). - "Call record_thread for genuinely open questions a future cycle should pursue." Let's see if we should open any new threads. Wait! A major open question is the outcome of the FDA Pharmacy Compounding Advisory Committee's recommendations: will the FDA formally adopt the committee's recommendation and add the six peptides to the 503A bulk drug substances list? Let's open a new thread for this! Wait, let's call `record_watch` instead if there's a forward-looking catalyst. "Call record_watch for anything forward-looking this cycle surfaced — a 'what to watch' that has a future trigger." Yes! The FDA's final decision/rule on the six compounding peptides (BPC-157, TB-500, KPV, MOTS-c, epitalon, semax) is a perfect ongoing or one-shot watch! Let's register a watch for this. And what about Capricor's AdCom? The meeting is on July 29, 2026. The watch `019f061f-f34a-7079-a276-d216329928b2` is already registered for this. What about Replimune's AdCom? The watch `019f0620-007b-7dab-87b4-0363a2496ea1` is already registered for this. What about Saol's SL1009 filing acceptance? The watch `019f67f8-1a98-7a61-a210-07071f61b308` is already registered for this. Let's register a new watch for the FDA's final decision on the compounding peptides. Let's do that!

This is fantastic. We have successfully registered a watch for the compounding peptides decision. Let's review if there are any threads we can resolve or if we should open any new threads. Wait! The threads listed are watches. We don't have open questions that aren't already monitored by watches. Let's call `finish_cycle` to end the research cycle. This is the ONLY way to complete a cycle. I will pass an empty string for `no_findings_reason` because we wrote several findings this cycle.

I have successfully completed the research cycle for this topic. Here is a summary of the major developments and findings recorded during this cycle: ### 1. **Capricor's Deramiocel Disputed by FDA Ahead of AdCom** * **Finding Updated:** `[[fda-regulatory-pivot-advisory-committees-capricor-replimune]]` * **Summary:** On July 27, 2026, the FDA released highly critical briefing documents ahead of the July 29 CTGTAC advisory committee meeting for Capricor's DMD cardiomyopathy cell therapy, **deramiocel**. The FDA reviewers flatly disputed Capricor's claims of Phase 3 success in the HOPE-3 trial, stating the trial did not meet pre-specified primary or secondary endpoints. The FDA criticized Capricor for making post-hoc, post-unblinding changes to the Statistical Analysis Plan (SAP) and highlighted safety profile differences (42% hypersensitivity reactions in deramiocel vs 15% in placebo) that could have unblinded the study. Following the release, Capricor's stock tumbled by over 65%. ### 2. **FDA Pharmacy Compounding Committee Backs Six Peptides** * **New Finding Created:** `[[fda-compounding-advisory-committee-peptide-recommendations]]` * **Summary:** In a landmark decision on July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding six out of seven nominated peptides to the 503A bulk drug substances list for compounding. The committee approved **BPC-157**, **KPV**, **TB-500**, and **MOTS-c** on July 23, and **epitalon** and **semax** on July 24, while rejecting **emideltide**. Notably, the committee repeatedly overrode formal FDA staff objections regarding potential immunogenicity, aggregation, and a lack of clinical trial data. This shift aligns with broader public health priorities supported by HHS Secretary Robert F. Kennedy, Jr. A new watch (`019fa5c3-dde6-7519-a517-b6ae4dc5fdbb`) was registered to track the FDA's final rulemaking on these recommendations. ### 3. **H5N1 Avian Influenza Expansion in Australia & New Zealand** * **Finding Updated:** `[[h5n1-avian-influenza-arrival-new-zealand-australia-poultry-lockdowns]]` * **Summary:** The H5N1 avian influenza strain continues to spread among wild bird populations in Oceania. In Australia, Queensland confirmed its first case on July 25, 2026, in a dead giant petrel on Moreton Island, making it the fourth state to detect the virus. On July 27, South Australia reported seven new suspected cases in greater crested terns on the Limestone Coast. In New Zealand, wild bird cases have prompted local wildlife sanctuaries (including the Wingspan National Bird of Prey Centre and Oamaru's penguin colony) to implement emergency biosecurity lockdowns, including shoe baths and visitor restrictions. Crucially, there remain no confirmed H5N1 detections in commercial poultry flocks on either mainland. ### 4. **Saol Therapeutics' SL1009 NDA Resubmission Details** * **Finding Updated:** `[[saol-sl1009-dca-fda-resubmission]]` * **Summary:** Saol Therapeutics' July 7, 2026, resubmission of its NDA for **SL1009 (sodium dichloroacetate / DCA)** in Pyruvate Dehydrogenase Complex Deficiency (PDCD) was highlighted. Details emerged showing that Saol aligned its resubmission package with the FDA through a Type A meeting in December and a subsequent Type C meeting, incorporating new historical control survival data. This resubmission is part of a wave of "post-Makary" regulatory realignments following the departures of Marty Makary and Vinay Prasad. The FDA's 30-day filing review is currently underway.